Immunoglobulin E specific for Stemphylium solani allergens (sIgE (Stemphylium solani))

IgE antibodies specific for Stemphylium solani allergens are specialized immunoglobulins that mediate Type I hypersensitivity reactions to this fungal pathogen. Stemphylium solani is a filamentous fungus known to cause gray leaf spot in plants and is a significant source of airborne allergens in humans. The primary allergen recognized by these antibodies is Ste s 1, a member of the Alt a 1 protein family that shows high cross-reactivity with other pleosporalean fungi (IUIS Allergen Nomenclature). In sensitized individuals, these specific IgE antibodies bind to the allergen and then attach to high-affinity IgE receptors (FcεRI) on the surface of mast cells and basophils. Upon re-exposure, the allergen cross-links the IgE-FcεRI complexes, triggering the rapid release of inflammatory mediators like histamine and leukotrienes (PubMed: 15985814). This process leads to clinical symptoms such as allergic rhinitis, conjunctivitis, and asthma. Therapeutic strategies include the use of anti-IgE monoclonal antibodies like Omalizumab, which sequester free IgE to prevent receptor binding, and allergen-specific immunotherapy (AIT) aimed at inducing immune tolerance (PubMed: 22405063). Monitoring serum levels of these antibodies serves as a critical biomarker for diagnosing fungal allergy and assessing treatment efficacy.

Other names

Anti-Stemphylium solani IgEStemphylium solani-specific IgEsIgE Stemphylium solaniSpecific IgE to Stemphylium solani

Neutralization of circulating IgE to prevent binding to high-affinity IgE receptors (FcεRI) on mast cells and basophils, thereby inhibiting the release of inflammatory mediators.